Company Overview
Company Type: Public Company
Website: nirvanalifescience.com
Number of Employees: -
Ticker: NIRV (CNSX)
Year Founded: -


Business Description
Nirvana Life Sciences Inc. engages in the scientific research and development of therapeutic products derived from psychedelics. The company also focuses on developing methodologies for extraction and purification of psychoactive compounds. Nirvana Life Sciences Inc. is headquartered in Vancouver, Canada.

Financial Information (Currency: CAD, in mm) 
Market Capitalization
2.4
EBITDA
(1.2)
Total Enterprise Value
2.5
TEV/EBITDA
NM
EBIT
(1.3)
Cash & ST Invst.
0.0
P/Diluted EPS Before Extra
NM
Net Income
(5.8)
Total Debt
0.1
Price/Tang BV
NM
Total Assets
0.4
Total Debt/EBITDA
NM
Currency in CAD in mm, LTM as of Jan-31-2023 TEV and Market Cap are calculated using a close price as of Oct-02-2023

Key Professionals
Name
Title
Clark, Bruce 
CEO & Director
Storey, Patricia Ann
CFO & Director
McCune, Michael 
Vice President of Operations
Hossain, Sazzad 
Chief Scientific Officer
August, Robert 
Head of Innovation
Nabissi, Massimo 
Head of Clinical Trials

Key Board Members
Name
Title
Clark, Bruce 
CEO & Director
Storey, Patricia Ann
CFO & Director
Inwentash, Sheldon 
Director
Lupton, Edward 
Director
Marissen, Mark 
Director
Samann, Andrew 
Member of Advisory Board


Primary Industry Classification
Pharmaceuticals


Primary Office Location
650 West Georgia Street Suite 2100 | Vancouver, BC | V6B 4N8 | Canada

Current and Pending Investors
ThreeD Capital Inc. (CNSX:IDK)

Stock Quote and Chart (Currency: CAD)
Last  (Delayed)
 0.05
Market Cap (mm)
2.4
Open
 0.05
Shares Out. (mm)
48.2
Previous Close
 0.05
Float %
60.0%
Change on Day
0.00
Shares Sold Short (mm)
-
Change % on Day
0.0%
Dividend Yield %
-
Day High/Low
 0.05/ 0.05
Diluted EPS Excl. Extra Items
(0.18)
52 wk High/Low
 0.25/ 0.02
P/Diluted EPS Before Extra
NM
Volume (mm)
0.0031
Avg 3M Dly Vlm (mm)
0.03
Beta 5Y
-


 
Delayed Quote** | Last Updated on Oct-02-2023 12:00 AM (GMT-5)


Company Notes
No Company Notes exist.


Strategy Notes
No Strategy Notes exist.


Current and Pending Subsidiaries / Investments
Company Name
Business Description
Geography
Primary Industry
LTM Total Rev.($mm)
LFQ Total Assets ($mm)
LFQ Total Debt ($mm)
Medsmart Dispensary Inc. (Pending)
Medsmart Dispensary Inc. engages in the distribution of herbal medicine that is designed to detoxify the human body. The company was incorporated in 2015 and is based in Vancouver, Canada.

United States and Canada
Drug Retail
-
-
-
Endocan Solutions Inc.
As of March 10, 2022, Endocan Solutions Inc. was acquired by Nirvana Life Sciences Inc., in a reverse merger transaction. Endocan Solutions Inc. engages in the acquisition of companies and assets in the medical marijuana sector. Endocan Solutions Inc. was formerly known as Worldwide Marijuana Inc. and changed its name to Endocan Solutions Inc. in August 2017. The company was incorporated in 2011 and is based in Vancouver, Canada.

United States and Canada
Pharmaceuticals
-
0.00
0.00


Last 5 Transactions
Announced Date
Closed Date
Transaction Type
Role
Target
Buyer/Investors
Sellers
Size($mm)
Jun-07-2023
-
Merger/Acquisition
Buyer
Medsmart Dispensary Inc.
Nirvana Life Sciences Inc. (CNSX:NIRV)

0.13
May-10-2023
-
Private Placement
Target
Nirvana Life Sciences Inc. (CNSX:NIRV)


-
Jun-01-2022
Jun-01-2022
Private Placement
Target
Nirvana Life Sciences Inc. (CNSX:NIRV)
ThreeD Capital Inc. (CNSX:IDK)

0.12
Jun-04-2021
Mar-10-2022
Merger/Acquisition
Buyer
Endocan Solutions Inc.
Nirvana Life Sciences Inc. (CNSX:NIRV)

8.16
Jun-04-2021
Sep-23-2021
Private Placement
Buyer
Endocan Solutions Inc.
Nirvana Life Sciences Inc. (CNSX:NIRV)

0.53
* denotes that the relationship is proprietary


Last 5 Key Developments
Date
Event Type
Headline
Aug-29-2023
Board Meeting
Nirvana Life Sciences Inc., Board Meeting, Aug 29, 2023
Jun-07-2023
M&A Transaction Announcements
Nirvana Life Sciences Inc. (CNSX:NIRV) has entered into a definitive agreement to acquire Medsmart Dispensary Inc. for $0.13 million.
May-10-2023
Private Placements
Nirvana Life Sciences Inc. announced a financing transaction
Feb-22-2023
Executive/Board Changes - Other
Nirvana Life Sciences Inc. Announces Resignation of Chris Hoffmeister from the Board of Directors
Nov-09-2022
Executive/Board Changes - Other
Nirvana Life Sciences Inc. Appoints Sheldon Inwentash to the Company's Board of Directors

M&A Advisors
Segev LLP


Advisors
Most Recent Auditor
Dale Matheson Carr-Hilton LaBonte LLP
M&A Advisors
Segev LLP


Most Recent Auditor
Dale Matheson Carr-Hilton


Last 10 Investment Research Documents
No Investment Research returned. This can be caused by entitlement settings or your template settings.


Ownership Summary

            Top Holders 
Holders by Type
Holder

Common Stock Equivalent Held

% of Total Shares Outstanding

Market Value (CAD in mm)

Position Date


Hossain M.Sc., Ph.D., Sazzad 

3,900,000

8.09

0.2

Mar-16-2022


Clark, Bruce 

3,706,666

7.68

0.2

May-17-2023


ThreeD Capital Inc.

3,575,000

7.41

0.2

Jun-09-2022


Rosiek, Randy 

3,250,000

6.74

0.2

Mar-16-2022


Inwentash B.Com., B.Comm., C.A., CPA, CA., CPA, LL.D. (Ho, Sheldon 

1,500,000

3.11

0.1

Feb-22-2023


McCune, Michael 

1,401,143

2.90

0.1

Feb-06-2023


Fretwell B.Com., B.Comm., L.L.B., LL.B., Gordon J.

1,100,001

2.28

0.1

May-12-2023


Inwentash, Jakson Samuel

500,000

1.04

0.0

Feb-22-2023


Storey B.B.A., BBA, C.A., CA, CPA, Patricia Ann

370,000

0.77

0.0

May-10-2023



 



Top Buyers
Buyers
Common Stock Equivalent Held
Change
Clark, Bruce 
3,706,666
2,000,000
Fretwell B.Com., B.Comm., L.L.B., LL.B., Gordon J.
1,100,001
1,100,001

Top Sellers
No Top Sellers data available.


S&P Global Ratings Credit Ratings
No S&P Global Ratings Credit Ratings data available. 


News Headlines
No News is currently available for the selected sources.


Company Coverage
This company is not on any Coverage List.

Products
Psilocybin Drugs (Future)


Recent Major Filings

Key Filings
Filed On
Period Date
Company Name
Source
Form Type
Size
Sep-29-2023
-
Nirvana Life Sciences Inc. (CNSX:NIRV)
SEDAR
News Releases
127 KB
Sep-13-2023
-
Nirvana Life Sciences Inc. (CNSX:NIRV)
SEDAR
News Releases
126 KB
Aug-30-2023
-
Nirvana Life Sciences Inc. (CNSX:NIRV)
SEDAR
Material Change Report
155 KB
Aug-30-2023
-
Nirvana Life Sciences Inc. (CNSX:NIRV)
SEDAR
News Releases
132 KB
Aug-21-2023
-
Nirvana Life Sciences Inc. (CNSX:NIRV)
SEDAR
Material Change Report
158 KB
Aug-21-2023
-
Nirvana Life Sciences Inc. (CNSX:NIRV)
SEDAR
News Releases
145 KB
Jun-07-2023
-
Nirvana Life Sciences Inc. (CNSX:NIRV)
SEDAR
News Releases
30 KB
May-10-2023
-
Nirvana Life Sciences Inc. (CNSX:NIRV)
SEDAR
Material Change Report
139 KB
May-10-2023
-
Nirvana Life Sciences Inc. (CNSX:NIRV)
SEDAR
News Releases
139 KB
Apr-03-2023
Jan-31-2023
Nirvana Life Sciences Inc. (CNSX:NIRV)
SEDAR
Interim Financial Statements
315 KB


Insider Trades
Holder Name
Trade Date Range
Security Type
Transacted Shares
Transaction Value Range (CAD)
Transaction Type
% Change
Source
Clark, Bruce  (CEO & Director)
May-17-2023
Common Shares
2,000,000
101,960
Private Acquisition
117.19
Multiple
Fretwell B.Com., B.Comm., L.L.B., LL.B., Gordon J.
May-12-2023
Common Shares
400,000
20,298
Private Acquisition
57.14
Multiple
McCune, Michael  (Vice President of Operations)
Feb-06-2023
Common Shares
(106,000)
(9,748)
Open Market Disposition
(7.03)
Multiple
Storey B.B.A., BBA, C.A., CA, CPA, Patricia Ann (CFO & Director)
Aug-08-2022
Common Shares
(5,500)
(2,059)
Open Market Disposition
(1.46)
Multiple
Storey B.B.A., BBA, C.A., CA, CPA, Patricia Ann (CFO & Director)
Jul-07-2022
Common Shares
(4,500)
(1,929)
Open Market Disposition
(1.18)
Multiple
Excluding Automatic Transactions
Key Board Members Details
Name
Title
Phone
Fax
Email
Clark, Bruce 
CEO & Director
604-401-8100
-

Storey, Patricia Ann
CFO & Director
-
-

Inwentash, Sheldon 
Director
-
-

Lupton, Edward 
Director
-
-

Marissen, Mark 
Director
-
-

Samann, Andrew 
Member of Advisory Board
-
-

* denotes that the relationship is proprietary

Key Executives and Professionals Details
Name
Title
Phone
Fax
Email
Clark, Bruce 
CEO & Director
604-401-8100
-

Storey, Patricia Ann
CFO & Director
-
-

McCune, Michael 
Vice President of Operations
-
-

Hossain, Sazzad 
Chief Scientific Officer
-
-

August, Robert 
Head of Innovation
-
-

Nabissi, Massimo 
Head of Clinical Trials
-
-

* denotes that the relationship is proprietary

Historical Equity Pricing Data supplied by Interactive Data Pricing and Reference Data LLC 
S&P Credit Ratings and Research provided by 
No content (including ratings, credit-related analyses and data, valuations, model, software or other application or output therefrom) or any part thereof (Content) may be modified, reverse engineered, reproduced or distributed in any form by any means, or stored in a database or retrieval system, without the prior written permission of S&P Global Market Intelligence or its affiliates (collectively, S&P Global). The Content shall not be used for any unlawful or unauthorized purposes. S&P Global and any third-party providers, as well as their directors, officers, shareholders, employees or agents (collectively S&P Global Parties) do not guarantee the accuracy, completeness, timeliness or availability of the Content. S&P Global Parties are not responsible for any errors or omissions (negligent or otherwise), regardless of the cause, for the results obtained from the use of the Content, or for the security or maintenance of any data input by the user. The Content is provided on an "as is" basis. S&P GLOBAL PARTIES DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING, BUT NOT LIMITED TO, ANY WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE, FREEDOM FROM BUGS, SOFTWARE ERRORS OR DEFECTS, THAT THE CONTENTâ€™S FUNCTIONING WILL BE UNINTERRUPTED OR THAT THE CONTENT WILL OPERATE WITH ANY SOFTWARE OR HARDWARE CONFIGURATION. In no event shall S&P Global Parties be liable to any party for any direct, indirect, incidental, exemplary, compensatory, punitive, special or consequential damages, costs, expenses, legal fees, or losses (including, without limitation, lost income or lost profits and opportunity costs or losses caused by negligence) in connection with any use of the Content even if advised of the possibility of such damages.

Credit-related and other analyses, including ratings, and statements in the Content are statements of opinion as of the date they are expressed and not statements of fact. S&P Global Market Intelligenceâ€™s opinions, analyses and rating acknowledgment decisions (described below) are not recommendations to purchase, hold, or sell any securities or to make any investment decisions, and do not address the suitability of any security. S&P Global Market Intelligence assumes no obligation to update the Content following publication in any form or format. The Content should not be relied on and is not a substitute for the skill, judgment and experience of the user, its management, employees, advisors and/or clients when making investment and other business decisions. S&P Global Market Intelligence does not act as a fiduciary or an investment advisor except where registered as such. While S&P Global Market Intelligence has obtained information from sources it believes to be reliable, S&P Global Market Intelligence does not perform an audit and undertakes no duty of due diligence or independent verification of any information it receives.

S&P Global keeps certain activities of its divisions separate from each other in order to preserve the independence and objectivity of their respective activities. As a result, certain divisions of S&P Global may have information that is not available to other S&P Global divisions. S&P Global has established policies and procedures to maintain the confidentiality of certain non-public information received in connection with each analytical process.

S&P Global Ratings does not contribute to or participate in the creation of credit scores generated by S&P Global Market Intelligence. Lowercase nomenclature is used to differentiate S&P Global Market Intelligence PD credit model scores from the credit ratings issued by S&P Global Ratings.

S&P Global may receive compensation for its ratings and certain analyses, normally from issuers or underwriters of securities or from obligors. S&P Global reserves the right to disseminate its opinions and analyses. S&P Global's public ratings and analyses are made available on its Web sites, www.standardandpoors.com (free of charge), and www.capitaliq.com (subscription), and may be distributed through other means, including via S&P Global publications and third-party redistributors. Additional information about our ratings fees is available at www.standardandpoors.com/usratingsfees.
Regulatory News Service data provided by 

**Intraday Quotes are delayed by at least 20 minutes.
